【摘 要】
：
Human Immunodeficiency virus (HIV) is composed of two viral types:HIV-1 and HIV-2.HIV-1 is pandemic.Sequence analysis of HIV-1 has allowed to classify this virus into three groups:M (major),O (outlier
【机 构】
：
Laboratoire de Virologie,Université de Bordeaux, France
【出 处】
：
2006中国天津世界艾滋病日科技会议
论文部分内容阅读
Human Immunodeficiency virus (HIV) is composed of two viral types:HIV-1 and HIV-2.HIV-1 is pandemic.Sequence analysis of HIV-1 has allowed to classify this virus into three groups:M (major),O (outlier) and N (neither M nor O,new); O and N are observed in Central Africa,particularly in Cameroon.Viruses belonging to group M are observed in all parts of the world.Group M is sub-divided in subtypes and CRFs (circulating recombinant forms); subtypes are A,B,C,D,F,G,H,J and K; 34 CRFs have been described:among them,CRF01_AE is a recombinant between subtype A and an ancestral E subtype; CRF02_AG is a recombinant between subtypes A and G.The geographic repartition of these subtypes and CRFs is different from one continent to the other.Subtype B is predominant in western Europe,north America and Australia; CRF02_AG is predominant in west Africa; subtype C is frequently observed in India and CRF0 1_AE in south east Asia,particularly in Vietnam and Cambodia.
其他文献
Viruses,by definition,are obligate intracellular pathogens and therefore,successful vaccination must induce cellmediated immunity for effective control and/or prevention of disease.Since HIV-1 is pred
FusoGen Pharmaceuticals,Inc.is a leading Chinese biotech company based in Tianjin and Beijing,China.The company was founded in 2002 by Jason G.Zhou,an expert in structural biology and computer-assiste
The HIV-1 reverse transcriptase (RT) has been a successful target for chemotherapeutic intervention.However,new drugs are urgently needed for systemic or for topical use as a microbicide due to the ev
NIFEVIROC,a small molecular compound,is a proprietary drug candidate which is developed by TARGETDRUG and holds great promise in inhibiting HIV-1 replication in infected paitents.Preclinical studies s
The continuing emergence of resistant strains of the human immunodeficiency virus type 1 (HIV-1) makes the search for new anti-HIV-1 agents very urgent One of the most attractive target for selective
Until the end of 2005,twenty-seven drags targeted to the human immunodeficiency virus (HIV) have been approved by the U.S.Food and Drug Administration (FDA).Although great progress has been made in th